ERBB2 and breast carcinoma: We tested both the activity and toxicity of α-DOTA-PRIT in mouse xenografts of human colorectal cancer (GPA33-expressing SW1222), breast cancer (HER2-expressing BT-474), and neuroblastoma (GD2-expressing IMR-32) as models for α-therapy of human solid tumors.